Sio Gene Therapies to Participate in Upcoming Conferences
March 29 2021 - 8:00AM
Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company
focused on developing gene therapies to radically improve the lives
of patients with neurodegenerative diseases, announced today that
the company will participate in select upcoming investor and
scientific conferences in April. Details can be found below.
Guggenheim Healthcare Talks: 2021 Genomic Medicines
& Rare Disease Day
Participation: |
Panel discussion and 1-on-1 investor meetings |
Panel Title: |
Emerging Approaches Targeting CNS
Indications Like FTD and GM1 |
Panel Presenter: |
Pavan Cheruvu, MD, Chief
Executive Officer |
Panel Date & Time: |
Thursday, April 1, 2021 at 12:00
PM ET |
Webcast: |
https://kvgo.com/guggenheim/sio-gene-therapies-april-2021 |
Alliance for Regenerative Medicine Cell & Gene
Meeting on the Mediterranean
Participation: |
Panel discussion and corporate presentation |
Panel Title: |
Innovation: Shortening the Path
to Commercialization in Advanced Therapies |
Panel Presenter: |
Parag V. Meswani, PharmD, Chief
Commercial Officer |
Date: |
April 6, 2021 |
The company
presentation and panel discussion will be available to view
on-demand throughout the entirety of the conference. Please visit
www.meetingonthemed.com for full information including
registration. |
NTSAD’s 43rd Annual
Family Conference
Participation: |
Presentations on GM1 and GM2 gangliosidosis (Tay-Sachs/Sandhoff
disease) programs |
Date & Time: |
April 23, 2021 from 2:00-4:00 PM
ET |
Both sessions will
occur concurrently and are available to all attendees who can
register for the event here. |
The company will also participate in a number of medical events
throughout April including the ACMG Annual Clinical Genetics
Meeting, AAN 2021 Virtual Annual Meeting, and the Virtual World
Orphan Drug Congress USA 2021.
About Sio Gene Therapies
Sio Gene Therapies combines cutting-edge science with bold
imagination to develop genetic medicines that aim to radically
improve the lives of patients. Our current pipeline of
clinical-stage candidates includes the first potentially curative
AAV-based gene therapies for GM1 gangliosidosis and
Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal
pediatric conditions caused by single gene deficiencies. We are
also expanding the reach of gene therapy to highly prevalent
conditions such as Parkinson’s disease, which affects millions of
patients globally. Led by an experienced team of gene therapy
development experts, and supported by collaborations with premier
academic, industry and patient advocacy organizations, Sio is
focused on accelerating its candidates through clinical trials to
liberate patients with debilitating diseases through the
transformational power of gene therapies. For more information,
visit www.siogtx.com.
Contacts:
Media
Josephine Belluardo, Ph.D. LifeSci Communications(646)
751-4361jo@lifescicomms.cominfo@siogtx.com
Investors and Analysts
Parag V. MeswaniSio Gene Therapies Inc.Chief Commercial
Officerinvestors@siogtx.com
Sio Gene Therapies (NASDAQ:SIOX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sio Gene Therapies (NASDAQ:SIOX)
Historical Stock Chart
From Jul 2023 to Jul 2024